Brooks Laboratories Limited (BROOKS.BO)
INR 162.3
(1.98%)
INR 162.3
(1.98%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 49.48 Million INR | -23.74% |
| 2022 | 64.89 Million INR | -71.36% |
| 2021 | 226.53 Million INR | -25.73% |
| 2020 | 305 Million INR | 11.97% |
| 2019 | 272.4 Million INR | -5.01% |
| 2018 | 286.77 Million INR | 4.89% |
| 2017 | 273.39 Million INR | 101.28% |
| 2016 | 135.82 Million INR | 154.65% |
| 2015 | 53.33 Million INR | 123.8% |
| 2014 | -224.1 Million INR | 24.92% |
| 2013 | -298.5 Million INR | -31.03% |
| 2012 | -227.81 Million INR | -22.13% |
| 2011 | -186.54 Million INR | -339.31% |
| 2010 | 77.95 Million INR | -28.89% |
| 2009 | 109.62 Million INR | -20.93% |
| 2008 | 138.64 Million INR | 94.55% |
| 2007 | 71.26 Million INR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | - INR | -100.0% |
| 2023 FY | 49.48 Million INR | -23.74% |
| 2023 Q2 | 40.1 Million INR | 272.97% |
| 2023 Q1 | 10.75 Million INR | -83.43% |
| 2023 Q3 | 5.03 Million INR | -87.45% |
| 2023 Q4 | 49.48 Million INR | 883.41% |
| 2022 Q4 | 64.89 Million INR | 491.79% |
| 2022 Q3 | 10.96 Million INR | -95.32% |
| 2022 Q2 | 234.27 Million INR | 514.88% |
| 2022 Q1 | 38.1 Million INR | -83.18% |
| 2022 FY | 64.89 Million INR | -71.36% |
| 2021 FY | 226.53 Million INR | -25.73% |
| 2021 Q1 | 17.03 Million INR | -94.41% |
| 2021 Q2 | 292.96 Million INR | 1619.49% |
| 2021 Q3 | 12.16 Million INR | -95.85% |
| 2021 Q4 | 226.53 Million INR | 1762.79% |
| 2020 Q3 | 13.72 Million INR | -94.68% |
| 2020 FY | 305 Million INR | 11.97% |
| 2020 Q1 | 3.96 Million INR | -98.55% |
| 2020 Q2 | 258.05 Million INR | 6416.54% |
| 2020 Q4 | 305 Million INR | 2121.63% |
| 2019 Q1 | 34.67 Million INR | -87.91% |
| 2019 Q2 | 266.35 Million INR | 668.11% |
| 2019 Q3 | 10.78 Million INR | -95.95% |
| 2019 Q4 | 272.4 Million INR | 2424.82% |
| 2019 FY | 272.4 Million INR | -5.01% |
| 2018 Q1 | 6.45 Million INR | -97.29% |
| 2018 FY | 286.77 Million INR | 4.89% |
| 2018 Q4 | 286.77 Million INR | 1954.37% |
| 2018 Q3 | 13.95 Million INR | -94.43% |
| 2018 Q2 | 250.77 Million INR | 3785.02% |
| 2017 Q1 | 18.36 Million INR | -83.52% |
| 2017 FY | 273.39 Million INR | 101.28% |
| 2017 Q4 | 238.37 Million INR | 712.36% |
| 2017 Q3 | 29.34 Million INR | -86.92% |
| 2017 Q2 | 224.38 Million INR | 1121.55% |
| 2016 Q4 | 111.43 Million INR | 360.71% |
| 2016 FY | 135.82 Million INR | 154.65% |
| 2016 Q3 | 24.18 Million INR | -58.07% |
| 2016 Q2 | 57.69 Million INR | 159.2% |
| 2016 Q1 | 22.25 Million INR | -58.27% |
| 2015 Q3 | 220.46 Million INR | 347.89% |
| 2015 Q4 | 53.33 Million INR | -75.81% |
| 2015 FY | 53.33 Million INR | 123.8% |
| 2015 Q1 | 229.22 Million INR | 202.29% |
| 2015 Q2 | -88.93 Million INR | -138.8% |
| 2014 Q2 | -223.26 Million INR | -174.45% |
| 2014 FY | -224.1 Million INR | 24.92% |
| 2014 Q4 | -224.1 Million INR | -194.9% |
| 2014 Q3 | 236.13 Million INR | 205.77% |
| 2014 Q1 | 299.88 Million INR | 200.46% |
| 2013 Q3 | 328.6 Million INR | 200.0% |
| 2013 FY | -298.5 Million INR | -31.03% |
| 2013 Q1 | 238.69 Million INR | 204.78% |
| 2013 Q2 | -328.6 Million INR | -237.66% |
| 2013 Q4 | -298.5 Million INR | -190.84% |
| 2012 Q2 | -200.9 Million INR | 0.0% |
| 2012 Q4 | -227.81 Million INR | 0.0% |
| 2012 FY | -227.81 Million INR | -22.13% |
| 2011 Q4 | -186.54 Million INR | 0.0% |
| 2011 FY | -186.54 Million INR | -339.31% |
| 2010 FY | 77.95 Million INR | -28.89% |
| 2009 FY | 109.62 Million INR | -20.93% |
| 2008 FY | 138.64 Million INR | 94.55% |
| 2007 FY | 71.26 Million INR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Ajanta Pharma Limited | -954.9 Million INR | 105.182% |
| Amrutanjan Health Care Limited | -248.79 Million INR | 119.89% |
| Sigachi Industries Limited | 859.94 Million INR | 94.246% |
| Bal Pharma Limited | 1.26 Billion INR | 96.084% |
| Ind-Swift Laboratories Limited | -4.15 Billion INR | 101.192% |
| Medico Remedies Limited | 78.67 Million INR | 37.104% |
| Lasa Supergenerics Limited | 205.79 Million INR | 75.955% |
| Venus Remedies Limited | -267.7 Million INR | 118.485% |
| Sun Pharma Advanced Research Company Limited | -941.8 Million INR | 105.254% |
| Alpa Laboratories Limited | 35.36 Million INR | -39.934% |
| Nectar Lifesciences Limited | 6.15 Billion INR | 99.196% |
| Shilpa Medicare Limited | 9.06 Billion INR | 99.454% |
| Aarti Drugs Limited | 5.54 Billion INR | 99.108% |
| Lupin Limited | 17.19 Billion INR | 99.712% |
| Aurobindo Pharma Limited | 3.69 Billion INR | 98.66% |
| Zydus Lifesciences Limited | 3.91 Billion INR | 98.735% |
| Windlas Biotech Limited | -273.04 Million INR | 118.124% |
| Suven Life Sciences Limited | -1.63 Billion INR | 103.031% |
| Eris Lifesciences Limited | 13.8 Billion INR | 99.642% |
| Valiant Laboratories Limited | -295.03 Million INR | 116.773% |
| J. B. Chemicals & Pharmaceuticals Limited | 2.82 Billion INR | 98.246% |
| Solara Active Pharma Sciences Limited | 10.02 Billion INR | 99.507% |
| Ipca Laboratories Limited | 11.41 Billion INR | 99.566% |
| Bliss GVS Pharma Limited | -1.15 Billion INR | 104.274% |
| Achyut Healthcare Limited | -3.74 Million INR | 1421.009% |
| Sun Pharmaceutical Industries Limited | -72.47 Billion INR | 100.068% |
| Bajaj HealthCare Limited | 3.29 Billion INR | 98.5% |
| RPG Life Sciences Limited | -364.7 Million INR | 113.569% |
| Mankind Pharma Limited | -9.9 Billion INR | 100.499% |
| Laurus Labs Limited | 24.38 Billion INR | 99.797% |
| Piramal Pharma Limited | 42.27 Billion INR | 99.883% |
| Syncom Formulations (India) Limited | 46.21 Million INR | -7.085% |
| Torrent Pharmaceuticals Limited | 31.83 Billion INR | 99.845% |
| Alembic Pharmaceuticals Limited | 3.86 Billion INR | 98.72% |
| Glenmark Pharmaceuticals Limited | -4.28 Billion INR | 101.155% |
| Unichem Laboratories Limited | 931.91 Million INR | 94.69% |
| Sequent Scientific Limited | 4.17 Billion INR | 98.816% |
| Novartis India Limited | -5.89 Billion INR | 100.84% |
| Wanbury Limited | 1.1 Billion INR | 95.525% |
| Suven Pharmaceuticals Limited | 144.97 Million INR | 65.867% |
| Wockhardt Limited | 18.27 Billion INR | 99.729% |
| Themis Medicare Limited | 764.96 Million INR | 93.531% |
| Jagsonpal Pharmaceuticals Limited | -1.38 Billion INR | 103.56% |
| Jubilant Pharmova Limited | 27.07 Billion INR | 99.817% |
| Glenmark Life Sciences Limited | -2.84 Billion INR | 101.741% |
| Dr. Reddy's Laboratories Limited | 12.91 Billion INR | 99.617% |
| Divi's Laboratories Limited | -39.77 Billion INR | 100.124% |
| NATCO Pharma Limited | -5.81 Billion INR | 100.851% |
| Gufic Biosciences Limited | 3.19 Billion INR | 98.451% |
| IOL Chemicals and Pharmaceuticals Limited | -1.1 Billion INR | 104.493% |
| Ind-Swift Limited | 9.5 Billion INR | 99.48% |
| Procter & Gamble Health Limited | -2.34 Billion INR | 102.108% |
| FDC Limited | -57.75 Million INR | 185.685% |
| Krebs Biochemicals & Industries Limited | 1.93 Billion INR | 97.44% |
| Granules India Limited | 9.28 Billion INR | 99.467% |
| Medicamen Biotech Limited | 160.31 Million INR | 69.133% |
| Alkem Laboratories Limited | -1.6 Billion INR | 103.075% |
| AstraZeneca Pharma India Limited | -5.01 Billion INR | 100.987% |
| Biofil Chemicals and Pharmaceuticals Limited | -18.44 Million INR | 368.27% |
| Megasoft Limited | 1.28 Billion INR | 96.151% |
| ZIM Laboratories Limited | 983.6 Million INR | 94.969% |
| Strides Pharma Science Limited | 23.25 Billion INR | 99.787% |
| Neuland Laboratories Limited | -214.05 Million INR | 123.118% |
| Morepen Laboratories Limited | -231.17 Million INR | 121.406% |
| Hikal Limited | 7.96 Billion INR | 99.379% |
| Indoco Remedies Limited | 6.47 Billion INR | 99.236% |
| Aarti Pharmalabs Limited | 2.61 Billion INR | 98.105% |
| Kilitch Drugs (India) Limited | 120.03 Million INR | 58.776% |
| Mangalam Drugs & Organics Limited | 975.81 Million INR | 94.929% |
| Hester Biosciences Limited | 2.29 Billion INR | 97.84% |